Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07142356 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Oct 2026 → Mar 2027
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Retension Pharmaceuticals. Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 24 → 34 locations Show 4 more changesShow less
    • Trial arms changed: 2 → 4
    • Eligibility criteria shortened, about 1,064 words
    • Secondary endpoints revised (8)
    • Study description shortened, about 414 words
  2. Primary endpoint(s) modifiedv6 Show 6 more changesShow less
    • Primary completion pushed from Oct 2026 to Mar 2027
    • Study sites: 22 to 24
    • Study completion date: May 2027 to Jun 2027
    • Eligibility criteria expanded, about 220 words
    • Secondary endpoints: 9 to 8
    • Study description expanded, about 5 words
  3. Study sites: 20 to 22v5
  4. Study sites: 3 to 20v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Oct 2025 to Oct 31, 2025
    v3
  6. Primary endpoint revised
    • Secondary endpoints revised (9)
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to measure the safety and efficacy of RTN-001 in adult participants with uncontrolled hypertension versus placebo.
Trial Details
NCT Number NCT07142356
Lead Sponsor Retension Pharmaceuticals. Inc.
Conditions
(from sponsor)		 Uncontrolled Hypertension
Related terms Heart Murmurs, Hypertension, Systolic Murmurs
Enrollment 280 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov